Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

December 22, 2022

https://www.globenewswire.com/news-release/2022/12/22/2578444/0/en/Affimed-Announces-Approval-of-Clinical-Trial-Application-in-France-for-a-Phase-1-Study-of-AFM28-in-Relapsed-Refractory-Acute-Myeloid-Leukemia.html

HEIDELBERG, Germany, Dec. 22, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq:AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that the ANSM has authorized a CTA for the phase 1 study of AFM28 (AFM28-101) in relapsed/refractory acute myeloid leukemia (AML).

Read more at globenewswire.com

Related news for (AFMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.